Celeste Yu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Celeste Yu has a total of 152 co-authors. Here are the top co-authors by number of shared publications:
- Philippe L. Bedard
Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
101 shared publications - Gregory J. Riely
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
60 shared publications - Jeremy Lyle Warner
Legorreta Cancer Center, Brown University, Providence, RI
60 shared publications - Jessica A. Lavery
Department of Epidemiology & Biostatistics, MSK, New York, New York
60 shared publications - Michele L. Lenoue-Newton
Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN
60 shared publications - Nikolaus Schultz
Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center
60 shared publications
Latest Publications
- Open Access
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from Circulating Cell-Free DNA Methylation Profiling Enables Detection, Distinction, and Estrogen Receptor Status Classification of Advanced Breast Cancer
This shows validation of the distinction signature.
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from Circulating Cell-Free DNA Methylation Profiling Enables Detection, Distinction, and Estrogen Receptor Status Classification of Advanced Breast Cancer
This shows validation of the distinction signature.
- Open Access
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 8 from Circulating Cell-Free DNA Methylation Profiling Enables Detection, Distinction, and Estrogen Receptor Status Classification of Advanced Breast Cancer
Transmission of the tissue signature to the cfMeDip signature for ER-status.
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 8 from Circulating Cell-Free DNA Methylation Profiling Enables Detection, Distinction, and Estrogen Receptor Status Classification of Advanced Breast Cancer
Transmission of the tissue signature to the cfMeDip signature for ER-status.
- Open Access
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 9 from Circulating Cell-Free DNA Methylation Profiling Enables Detection, Distinction, and Estrogen Receptor Status Classification of Advanced Breast Cancer
Validation of the ER-signature.
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 9 from Circulating Cell-Free DNA Methylation Profiling Enables Detection, Distinction, and Estrogen Receptor Status Classification of Advanced Breast Cancer
Validation of the ER-signature.
- Open Access
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Tables 1-9 from Circulating Cell-Free DNA Methylation Profiling Enables Detection, Distinction, and Estrogen Receptor Status Classification of Advanced Breast Cancer
Supplementary Tables 1-9 from Circulating Cell-Free DNA Methylation Profiling Enables Detection, Distinction, and Estrogen Receptor Status Classification of Advanced Breast Cancer
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables 1-9 from Circulating Cell-Free DNA Methylation Profiling Enables Detection, Distinction, and Estrogen Receptor Status Classification of Advanced Breast Cancer
Supplementary Tables 1-9 from Circulating Cell-Free DNA Methylation Profiling Enables Detection, Distinction, and Estrogen Receptor Status Classification of Advanced Breast Cancer
- Open Access
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Data from Circulating Cell-Free DNA Methylation Profiling Enables Detection, Distinction, and Estrogen Receptor Status Classification of Advanced Breast Cancer
The management of metastatic breast cancer (mBC) relies on tissue-based immunohistochemical subtypes. However, biopsies are invasive and may not capture metastatic heterogeneity, and subtypes can change over time under treatment pressure. In this study, we developed cell-free DNA (cfDNA) methylation signatures for minimally invasive breast cancer detection, distinction, and estrogen receptor (ER) status classification. Peripheral blood plasma methylomes were analyzed from 79 patients with mBC spanning ER+/human epidermal growth factor receptor 2 (HER2)− (n = 45), HER2+ (n = 13), and triple-negative breast cancer (n = 21). To derive tissue-informed breast cancer and ER-specific features, public 450K methylation array data (n = 9,730) were leveraged, and features were selected using generalized linear models via elastic net regularization with cross-validation. The tissue-informed features were translated to cell-free methylated DNA immunoprecipitation and sequencing (cfMeDIP-seq), and the final signatures were validated across a compendium of cfMeDIP-seq profiles (n = 713) spanning more than 10 cancer types. Across training, validation, and external test cohorts, the signatures demonstrated high accuracy for breast cancer detection versus controls, distinction from multiple other malignancies, and ER status classification. Performance generalized across independent cfMeDIP-seq cohorts and reflected tumor fraction. The sensitivity was reduced in samples with low tumor fractions and bone-only disease while remaining informative for typical tumor fractions observed in the metastatic setting. Promoter-proximal signature regions provided biological insight into tumor phenotypes. This tissue-anchored, platform-translatable framework demonstrates the feasibility of accurate, reproducible cfDNA methylation-based molecular classification in mBC. Significance:Tissue-anchored cell-free DNA methylation signatures enable minimally invasive detection, cancer-type distinction, and estrogen receptor classification in metastatic breast cancer, offering an interpretable, cross-platform framework to complement tissue biopsies for guiding subtype-directed therapy.
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Circulating Cell-Free DNA Methylation Profiling Enables Detection, Distinction, and Estrogen Receptor Status Classification of Advanced Breast Cancer
The management of metastatic breast cancer (mBC) relies on tissue-based immunohistochemical subtypes. However, biopsies are invasive and may not capture metastatic heterogeneity, and subtypes can change over time under treatment pressure. In this study, we developed cell-free DNA (cfDNA) methylation signatures for minimally invasive breast cancer detection, distinction, and estrogen receptor (ER) status classification. Peripheral blood plasma methylomes were analyzed from 79 patients with mBC spanning ER+/human epidermal growth factor receptor 2 (HER2)− (n = 45), HER2+ (n = 13), and triple-negative breast cancer (n = 21). To derive tissue-informed breast cancer and ER-specific features, public 450K methylation array data (n = 9,730) were leveraged, and features were selected using generalized linear models via elastic net regularization with cross-validation. The tissue-informed features were translated to cell-free methylated DNA immunoprecipitation and sequencing (cfMeDIP-seq), and the final signatures were validated across a compendium of cfMeDIP-seq profiles (n = 713) spanning more than 10 cancer types. Across training, validation, and external test cohorts, the signatures demonstrated high accuracy for breast cancer detection versus controls, distinction from multiple other malignancies, and ER status classification. Performance generalized across independent cfMeDIP-seq cohorts and reflected tumor fraction. The sensitivity was reduced in samples with low tumor fractions and bone-only disease while remaining informative for typical tumor fractions observed in the metastatic setting. Promoter-proximal signature regions provided biological insight into tumor phenotypes. This tissue-anchored, platform-translatable framework demonstrates the feasibility of accurate, reproducible cfDNA methylation-based molecular classification in mBC. Significance:Tissue-anchored cell-free DNA methylation signatures enable minimally invasive detection, cancer-type distinction, and estrogen receptor classification in metastatic breast cancer, offering an interpretable, cross-platform framework to complement tissue biopsies for guiding subtype-directed therapy.
- Open Access
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Circulating Cell-Free DNA Methylation Profiling Enables Detection, Distinction, and Estrogen Receptor Status Classification of Advanced Breast Cancer
This shows cohort characteristics and approach.
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Circulating Cell-Free DNA Methylation Profiling Enables Detection, Distinction, and Estrogen Receptor Status Classification of Advanced Breast Cancer
This shows cohort characteristics and approach.
- Open Access
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Circulating Cell-Free DNA Methylation Profiling Enables Detection, Distinction, and Estrogen Receptor Status Classification of Advanced Breast Cancer
This shows how the signature was developed.
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Circulating Cell-Free DNA Methylation Profiling Enables Detection, Distinction, and Estrogen Receptor Status Classification of Advanced Breast Cancer
This shows how the signature was developed.
- Open Access
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from Circulating Cell-Free DNA Methylation Profiling Enables Detection, Distinction, and Estrogen Receptor Status Classification of Advanced Breast Cancer
Illustration of how this was translated to the liquid biopsy space.
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from Circulating Cell-Free DNA Methylation Profiling Enables Detection, Distinction, and Estrogen Receptor Status Classification of Advanced Breast Cancer
Illustration of how this was translated to the liquid biopsy space.
- Open Access
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 6 from Circulating Cell-Free DNA Methylation Profiling Enables Detection, Distinction, and Estrogen Receptor Status Classification of Advanced Breast Cancer
This looks at detection and distinction signature combined together.
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 6 from Circulating Cell-Free DNA Methylation Profiling Enables Detection, Distinction, and Estrogen Receptor Status Classification of Advanced Breast Cancer
This looks at detection and distinction signature combined together.
- Open Access
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 7 from Circulating Cell-Free DNA Methylation Profiling Enables Detection, Distinction, and Estrogen Receptor Status Classification of Advanced Breast Cancer
Receptor subtype generation approach.
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 7 from Circulating Cell-Free DNA Methylation Profiling Enables Detection, Distinction, and Estrogen Receptor Status Classification of Advanced Breast Cancer
Receptor subtype generation approach.